Eledon Pharmaceuticals
ELDN
27 hedge funds and large institutions have $14.3M invested in Eledon Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 5 closing their positions.
0.25% less ownership
Funds ownership: 45.55% → 45.3% (-0.25%)
13% less funds holding
Funds holding: 31 → 27 (-4)
17% less capital invested
Capital invested by funds: $17.3M → $14.3M (-$2.96M)
25% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 8
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$879K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$7.36K |
| 3 |
BlackRock
New York
|
+$5.94K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.11K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$776 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.03M |
| 2 |
Two Sigma Advisers
New York
|
-$41K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
-$25.2K |
| 4 |
Two Sigma Investments
New York
|
-$20K |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$13.9K |
ELDN Hedge Fund Activity: Q4 2022 in Review
27 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q4 2022, worth a combined $14.3M — down 17% from $17.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ELDN and 2 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 6 added.
The largest buyer was Ensign Peak Advisors, adding an estimated $879K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.03M sold.
- 27 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q4 2022, down from 31 in Q3 2022.
- Funds reported $14.3M of Eledon Pharmaceuticals stock for Q4 2022, down 17% quarter-over-quarter.
- 2 funds opened new Eledon Pharmaceuticals positions in Q4 2022 and 5 closed out, a net change of -3 holders.
- The largest Eledon Pharmaceuticals buyer in Q4 2022 was Ensign Peak Advisors, an estimated $879K added.
- The largest Eledon Pharmaceuticals seller in Q4 2022 was Point72 Asset Management, an estimated $1.03M sold.
Based on aggregated 13F filings for Q4 2022.